Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Larimar Therapeutics Inc
LRMR
Healthcare
Biotechnology
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an...
essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:LRMR)
New Post
View:
Posts & Comments
Threaded Posts
(269)
•••
whytestocks
X
Post by
whytestocks
on Nov 18, 2024 8:00pm
Larimar Therapeutics Presents Additional Data from Phase 1 S
NEWS: $LRMR Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024Treatment with nomlabofusp
...more
(269)
•••
whytestocks
X
Post by
whytestocks
on Oct 30, 2024 1:45pm
Larimar Therapeutics Reports Third Quarter 2024 Operating an
Breaking News: $LRMR Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsNomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK
...more
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(269)
•••
whytestocks
X
Post by
whytestocks
on Oct 03, 2024 10:32am
LRMR Price Target Alert: $22.00. Issued by Wedbush
BREAKING NEWS: $LRMR LRMR Price Target Alert: $22.00. Issued by Wedbush2024-10-03 09:59:47 ET Laura Chico from Wedbush issued a price target of $22.00 for LRMR on 2024-10-03 08:28:00. The adjusted
...more
(269)
•••
whytestocks
X
Post by
whytestocks
on May 21, 2024 3:00pm
Larimar Therapeutics' Friedreich's Ataxia Investigational Dr
News; $LRMR Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug | BenzingaOn Monday,@Larimar Therapeutics@Inc@(NASDAQ:LRMR) announced
...more
(269)
•••
whytestocks
X
Post by
whytestocks
on Feb 13, 2024 11:15am
Larimar Therapeutics Inc. (NASDAQ: LRMR) Leading the Way in
Just In: $LRMR Larimar Therapeutics Inc. (NASDAQ: LRMR) Leading the Way in Tuesday Trading Based on Percentage GainLarimar Therapeutics, Inc. (NASDAQ: LRMR) is one of today's top gainers. The
...more
(269)
•••
whytestocks
X
Post by
whytestocks
on Feb 12, 2024 8:30pm
Why Is Inherited Rare Disease Focused-Larimar Therapeutics S
Just In: $LRMR Why Is Inherited Rare Disease Focused-Larimar Therapeutics Stock Trading Lower Today? | BenzingaLarimar Therapeutics Inc@(NASDAQ:LRMR) released topline data and completed its four-week,
...more
(269)
•••
whytestocks
X
Post by
whytestocks
on Feb 12, 2024 8:15pm
Larimar Therapeutics Reports Positive Top-line Data from Pha
BREAKING NEWS: $LRMR Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia
...more
(269)
•••
whytestocks
X
Post by
whytestocks
on Feb 12, 2024 8:00pm
Larimar Therapeutics Reports Positive Top-line Data from Pha
JUST IN: $LRMR Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's AtaxiaNomlabofusp
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
Featured News Links
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments